Case Report: Bevacizumab combined with chemotherapy followed by PARP inhibitor maintenance therapy in POLE-mutated primary fallopian tube carcinoma: a case of precision treatment in a rare gynecologic malignancy

This case demonstrates that Bev combined with chemotherapy may be an effective first-line regimen for this rare PTC variant. Maintenance therapy with a PARP inhibitor may prolong progression-free survival.